Amberstone Biosciences discovers novel immunotherapies through innovative technologies and creative partnerships.
Amberstone Biosciences has raised $12.0M in total funding. The most recent round was Series A. The last funding was announced in January 2022.
Amberstone Biosciences's investors include National Science Foundation, Sinovation Ventures, Cowin Venture, Viva BioInnovator, Xiamen Changrong Investment Management.
Amberstone Biosciences is headquartered in Laguna Hills, United States.
Amberstone Biosciences discovers novel immunotherapies through innovative technologies and creative partnerships.
Amberstone Biosciences is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Amberstone Biosciences — Funding & Investors." VCBacked, January 3, 2022, https://www.vcbacked.co/company/amberstone-biosciences. Accessed August 14, 2026.
VCBacked. (2022). Amberstone Biosciences — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/amberstone-biosciences
{{cite web |title=Amberstone Biosciences — Funding & Investors |url=https://www.vcbacked.co/company/amberstone-biosciences |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated